These findings suggest that rs822336, through its effect on PD-L1 expression, could serve as a biomarker for predicting the efficacy of PD-1/PD-L1-based immunotherapy in advanced NSCLC (22, 23). Here, PDCD1 is linked to non-small cell lung carcinoma.